Reaction

Gastric Bypass reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,149 reports · 50 co-occurring drugs

As of the last recalculation, Gastric Bypass appears in 2,149 FAERS reports alongside 50 co-occurring drug terms. The strongest observed disproportionality signal is CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES (PRR 26.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Calcium, Magnesium, Potassium, And Sodium Oxybates	23	26.1	26.2
Sodium Oxybate	102	15.7	15.7
Naltrexone Hydrochloride And Bupropion Hydrochloride	11	12.6	12.6
Pancrelipase	46	11.8	11.8
Armodafinil	25	11.6	11.6
Lurasidone Hydrochloride	23	10.8	10.8
Etonogestrel And Ethinyl Estradiol	23	10.1	10.2
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, And Amphetamine Sulfate	36	10.0	10.0
Ziprasidone Mesylate	14	9.6	9.6
Cariprazine	9	9.4	9.4
Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate And Amphetamine Aspartate	38	9.0	9.0
Duloxetine Hydrochloride	162	9.0	9.0
Buspirone Hydrochloride	10	8.8	8.8
Rizatriptan Benzoate	9	8.6	8.6
Modafinil	28	8.5	8.5
Ziprasidone	14	7.7	7.7
Methylphenidate Hydrochloride	46	7.7	7.7
Interferon Beta-1A	143	7.6	7.6
Risankizumab-Rzaa	53	6.4	6.4
Upadacitinib	50	6.1	6.1
Dofetilide	6	5.5	5.5
Dolutegravir Sodium	5	5.4	5.4
Peginterferon Beta-1A	7	5.2	5.2
Etonogestrel	24	4.9	4.9
Atazanavir	7	4.7	4.7
Oral Semaglutide	33	4.4	4.4
Lisdexamfetamine Dimesylate	14	4.1	4.1
Vortioxetine	7	4.0	4.0
Desvenlafaxine Succinate	11	4.0	4.0
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	4	3.9	3.9
Velpatasvir And Sofosbuvir	5	3.8	3.8
Brexpiprazole	6	3.5	3.5
Natalizumab	61	3.3	3.3
Bosutinib	3	3.2	3.2
Eptinezumab-Jjmr	3	3.2	3.2
Naltrexone	10	3.2	3.2
Exenatide	17	3.1	3.1
Rimegepant Sulfate	4	3.1	3.1
Dimethyl Fumarate	38	3.0	3.0
Orlistat	7	2.6	2.6
Canagliflozin	8	2.6	2.6
Emtricitabine And Tenofovir Alafenamide	3	2.6	2.6
Ambrisentan	31	2.4	2.4
Valbenazine	6	2.3	2.3
Esketamine Hydrochloride	4	2.2	2.2
Bimekizumab	4	1.8	1.8
Erenumab-Aooe	10	1.8	1.8
Guselkumab	6	1.6	1.6
Cinacalcet Hydrochloride	6	1.2	1.2
Galcanezumab-Gnlm	4	1.2	1.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.